Capstone Therapeutics announced consolidated earnings results for the year ended December 31, 2013. For the year, the company reported net loss attributable to stock holders of $3,921,000 or $0.10 basic and diluted per share compared to net loss attributable to stock holders of $3,580,000 or $0.09 basic and diluted per share of prior year. Loss from continuing operations was $4,114,000 against $4,053,000 of prior year.